Lentiviral vector integration sites in human NOD/SCID repopulating cells

Area of Science:

• Gene therapy
• Molecular biology
• Virology

Background:

• Insertional mutagenesis is a critical concern for gene therapy vectors.
• Understanding lentiviral vector integration site profiles is essential for safety assessments.
• Preclinical and clinical studies highlight the need to investigate vector integration patterns.

Purpose of the Study:

• To comprehensively investigate the spectrum of integration sites targeted by lentiviral vectors.
• To compare lentiviral vector integration profiles with those of gammaretroviral vectors.
• To assess the safety implications of lentiviral vector integration in human progenitor cells.

Main Methods:

• Lentiviral vector-mediated transduction of human cord blood (CB) progenitor cells.
• Transplantation of transduced cells into NOD/SCID mice.
• Ligation-mediated polymerase chain reaction (LM-PCR) to identify proviral integration sites in engrafted cells.
• Analysis of integration site distribution relative to gene features and transcriptional start sites.

Main Results:

• Lentiviral vector transduction efficiency of CD34(+) CB cells was 41%.
• Engraftment of EGFP(+) cells was observed, increasing from 65% at 3 weeks to 75% at 12 weeks post-transplantation.
• Sixty-eight percent of integrations occurred within RefSeq genes, predominantly in introns.
• Integrations near transcription start sites were significantly lower (20%) compared to gammaretroviral vectors.
• Sixty-two percent of integrations were in genes involved in cell metabolism; four were in genes associated with tumorigenesis.

Conclusions:

• Lentiviral vector integration in human repopulating cells preferentially targets coding regions.
• Integration clustering near transcriptional start sites is less pronounced for lentiviral vectors than for gammaretroviral vectors.
• These findings contribute to the safety profile evaluation of lentiviral vectors for gene therapy applications.